Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease Next Article
DECLARE TIMI-58 trial shows benefits of dapagliflozin in high-risk subgroups »
« 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease Next Article
DECLARE TIMI-58 trial shows benefits of dapagliflozin in high-risk subgroups »
Table of Contents: ACC 2019
Featured articles
Acute and Stable Ischaemic Heart Disease
Arrhythmias and Clinical Electrophysiology
Substantial impact of temporary interruptions of warfarin versus DOAC
Smartwatch can detect atrial fibrillation with high degree of accuracy
Congenital Heart Disease
Heart Failure and Cardiomyopathies
Frequent use of beta-blocker after HFpEF hospitalisations in elderly patients without compelling indications
High 5-year survival rates for older HF patients without initial severe comorbidity
Pulmonary Arterial Hypertension and Venous Thromboembolism
Interventional Cardiology
Vascular Medicine
Lower rates stroke/SE with DOACs in frail non-valvular AF patients
Similar rates of stroke/SE associated with DOAC vs warfarin use in obese non-valvular AF patients: Results from an observational registry
Convincing evidence of the role of icosapent in reducing subsequent CV events
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy